Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback